Q2 2021 Results - Reimagining Medicine

Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations EntrestoⓇ (ARNI) - Angiotensin II Receptor Neprilysin Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03066804 PARALLAX (CLCZ696D2302) Heart failure, preserved ejection fraction Phase 3 2572 Change in NT-proBNP from baseline to week 12 and change in 6 minute walk distance (6MWD) from baseline to Week 24 Sacubitril/valsartan 50 mg, 100 mg and 200 mg bid and matching placebo Enalapril 2.5 mg, 5 mg and 10 mg bid and matching placebo Valsartan 40 mg, 80 mg, 160 mg bid and matching placebo Heart failure patients (NYHA Class II-IV) with preserved ejection fraction Target Patients Read-out Milesstone(s) 2019 (actual) Publication Primary data publication in High Tier Journal 2021 NCT03785405 (CLCZ696B2319E1 - extension study) Heart failure in pediatric patients Phase 3 240 Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Single arm, open label sacubitril/valsartan (pediatric formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid)) Pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319 2023 TBD 60 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation